SLC18A2 and thanatophoric dysplasia: Having established NHP-human [18F]AV-133 PET translatability, NHP PET was used to estimate the %TO needed for effective treatment of tardive dyskinesia (TD) by valbenazine, an FDA-approved VMAT2 inhibitor.